Follow Us:
PARS‑PYP is a sterile, non‑pyrogen lyophilized radiopharmaceutical kit for the diagnosis of cardiac amyloidosis, which, after radiolabeling with Tc‑99m, is used for evaluation of this condition via SPECT imaging. The PYP kit is intended solely for diagnostic use and for the preparation of 99mTc‑Pyrophosphate.
- Diagnosis and management of cardiac amyloidosis
- Diagnosis of ATTR (Transthyretin Amyloidosis) without the need for cardiac biopsy
- Differentiation between types of amyloidosis, i.e., ATTR and AL (Amyloid Light), aiding in therapeutic decision‑making
- Evaluation of unexplained ventricular wall thickening
- Early diagnosis of cardiac amyloidosis in elderly patients with unexplained cardiomyopathy
After intravenous administration, 99mTc‑Pyrophosphate predominantly binds to microcalcifications and mineral changes associated with amyloid deposits formed in the heart wall. This binding, particularly in the ATTR type, leads to accumulation of the radiopharmaceutical in the affected areas, enabling imaging, whereas in the AL type, this accumulation is less pronounced.
The PARS‑PYP® kit is manufactured under aseptic conditions. After radiolabeling with a specified amount of sterile, non‑pyrogen sodium pertechnetate injection (Na99mTcO₄) — eluted from a 99Mo/99mTc generator — the preparation is ready for intravenous administration. The dose to be used will be prescribed by the physician.
Sodium Pyrophosphate Decahydrate (14 mg)
Stannous Chloride Dihydrate
Ascorbic Acid


